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Burden  of  rotavirus  gastroenteritis  (RVGE)  in  outpatient  setting  in  India  is  not  fully  understood.  A prospec-
tive  study  was  undertaken  to describe  RVGE  among  Indian  children  less  than  5 years  of age  presenting
in  outpatient  departments  with  acute  gastroenteritis  (AGE).  This  study  was  conducted  at  11  outpatient
departments  (OPDs)  of  private  pediatric  clinics  in urban  areas  of  India.  A  total  of  605  eligible children
were  enrolled  at  OPDs.  Stool  samples  of  the  subjects  were  collected  and  tested  for  presence  of rotavirus
antigen  by  enzyme  immune  assay  (EIA)  and  were  typed  by reverse-transcriptase  polymerase  chain  reac-
tion (RT-PCR).  Physician  examined  the  children  and  documented  the disease  particulars.  In  addition,
parents/guardians  were  interviewed  for  AGE  related  symptoms,  health  care  utilization  and  cost  incurred
due  to AGE,  and  parental  stress  associated  with  AGE.  After  OPD,  parents/guardians  completed  diary  cards
and  questionnaires  to capture  the information  for  14  days  following  the enrollment.
Complete  data  for  analysis  including  stool  sample  results  was  available  from  552 subjects.  23%
(127/552;  [CI  19.5,  26.5])  of  stool samples  were  rotavirus  (RV)  positive.  RT-PCR  was  done  for  85.8%
(109/127)  of RV positive  samples.  G1,  G2, G9,  and G12  types  were  identiﬁed  in  34.9%  (38/109),  37.6%
(41/109),  8.3%  (9/109),  and  6.4% (7/109)  stool  samples,  respectively.  P[4]  and  P[8] were  identiﬁed  in
36.7%  (40/109)  stool  samples  each,  followed  by P[6]  identiﬁed  in  15.6%  (17/109)  stool  samples.
At the  time  of  enrollment,  all three  symptoms  (vomiting,  diarrhea,  and  fever)  were observed  concur-
rently  in  higher  proportion  of RV  positive  subjects  compared  to  RV  negative  subjects  (60.6%  [77/127]  vs.
42.8%  [182/425],  p =  0.0004).  Healthcare  resource  utilization,  costs  incurred  due  to  disease,  and  parental
stress  were  higher  for RV  positive  subjects  compared  to RV negative  subjects.
In  conclusion,  RVGE  was  found  to  be  a deﬁnite  burden  in  AGE  cases  attending  pediatric  outpatient  clinics
in  urban  areas and it was associated  with  substantial  economic  and  psychological  burden.  Introduction
of  rotavirus  vaccine  in  India  may  help  in reducing  this  disease  burden.
d  by © 2014  Publishe Clinical Trials Registry-India (CTRI) registration number: CTRI/2012/02/002402.
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1. Introduction
The burden of diarrhea caused by rotavirus infection in the
pediatric population is a major cause of concern worldwide. It is
estimated that in 2008, rotavirus diarrhea or rotavirus gastroen-
teritis (RVGE) resulted in 453,000 deaths worldwide in children
aged less than 5 years, which accounted for 5% of all deaths in
this age group [1]. This estimate is after excluding the post vaccine
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ntroduction data if any. India alone accounted for approximately
2% of world RVGE deaths (98,621 deaths) in children aged less than
 years [1]. These ﬁgures clearly indicate high burden of rotavirus
ortality among Indian children. Rotavirus associated morbidity in
ndia is also well documented. Many Indian studies including the
ndian Rotavirus Strain Surveillance Network (IRSN) have evaluated
VGE burden amongst hospitalized cases of acute gastroenteritis
AGE) and some studies also demonstrated rotaviruses strain diver-
ity as in other developing countries [2–6]. These hospital based
tudies included testing stool samples for rotavirus and to deter-
ine the causative rotavirus strains. However, well designed study
ata is not available with respect to burden of RVGE as well as
ausative rotavirus strains when AGE cases are enrolled in pediatric
utpatient settings and are followed up for the disease spectrum.
e conducted an observational study to understand the epidemio-
ogical proﬁle of RVGE in private outpatient settings in India. Earlier
eports of studies conducted in hospitalized settings probably rep-
esent severe cases of RVGE that needed hospitalization, while the
resent study aimed to include information on disease caused by
VGE which is seen ﬁrst in the outpatient department (OPD). The
bjective of the study was to describe RVGE in children aged less
han 5 years who attended OPDs of private pediatric clinics in urban
reas. Accordingly stool samples of AGE subjects were tested to
etermine rotavirus positivity and RV positive samples were tested
or G and P types. Other characteristics of RVGE like clinical pre-
entation, severity, economical and psychological impact on the
arents/family of the children were also studied and compared to
on-RVGE.
. Materials and methods
.1. Study design
This was an observational, prospective study conducted at 11
ites located in urban areas across all ﬁve geographical (north,
outh, east, west, and central) regions of the country. Children less
han 5 years of age who attended the OPD of private pediatric clinics
or the treatment of AGE were enrolled. The study was conducted
ver a period of 11 months (15 December 2011–14 November
012); however individual sites differed in their study duration due
o variation in AGE burden and monthly enrollment rate.
.2. Study population
Parents/guardians of children aged less than 5 years (60 months)
ho suffered from AGE and attended OPD, were informed about
he study in detail. Children who met  the eligibility criteria were
ncluded in the study after written informed consent obtained from
he parents/guardians. AGE was deﬁned as three or more loose or
atery stools and/or one or more episodes of forceful vomiting in
 24-h period. These symptoms must have occurred within 3 days
rior to the OPD visit. Children who were enrolled in any other trial,
r had history of rotavirus infection, or had received a rotavirus vac-
ine were excluded. Children with any such condition that in the
pinion of the investigator could interfere with the study objec-
ives were excluded. Children whose parents were unable to give
onsent were also excluded.
.3. Data collection
After receiving written informed consent, the following
nformation was gathered from the parent/guardian using ques-
ionnaire: subject’s demographics including medical history,
ocio-economic details (e.g. annual family income, area of res-
dence), and family details (e.g. number of members in family,
umber of siblings); information about direct costs (e.g. OPD, 32S (2014) A36–A44 A37
medicines, extra drinking ﬂuids, expenses on conveyance for visit),
and impact caused by RVGE (e.g. monetary impact of lost days
of work for parent/guardian and parental stress). The monetary
impact of lost days of work was calculated based on daily wages
of the parent/guardian. The stress suffered by the parent/guardian
due to child’s disease was scored on a scale of 0–10, where ‘0’ was
no stress and ‘10’ was extreme stress.
At enrollment, following detailed clinical data were recorded
using questionnaire: date of onset of symptoms (diarrhea, vomi-
ting, and fever), number of days for which each symptom
continued, maximum frequency of stools and vomiting episodes
per day, maximum temperature recorded, dehydration status,
behavioral signs and symptoms, and treatment given to the sub-
ject. The severity of dehydration of the subject was  assessed as mild,
moderate, or severe by the investigator based on patient examina-
tion for restlessness, lethargy, sunken eyes, skin pinch, normal or
poor feeding. The number of IV rehydration bottles administered
to the subject was also recorded. Occurrences of behavioral signs
and symptoms such as irritable/less playful, lethargic/listless, and
convulsions were also recorded. The parent/guardian was given a
diary card and questionnaires to record follow-up information on
daily symptoms of the subject, and costs and impact caused due to
the disease. The questionnaire used on the day of enrollment and
follow-up questionnaires used to collect information after OPD visit
or Day 1 were designed speciﬁcally for this study, and contained
simple and easily understandable questions in local vernacular lan-
guage. The parent/guardian was  trained to ﬁll the diary card and
questionnaires.
Study personnel made two telephonic contacts with the par-
ent/guardian, ﬁrst after Day 7 and second after Day 14, for collecting
follow-up information for Day 1–Day 7 and Day 8–Day 14, respec-
tively. Additional information such as healthcare utilization (e.g.
repeat OPD visit/s, hospitalization, intravenous [IV] hydration) and
impact of disease and its progress during Day 1–Day 7 and Day
8–Day 14 was  also collected telephonically.
2.4. Assessment of severity
The severity of AGE was  scored by the physician based on phys-
ical examination of child and the information collected for the
duration and severity of disease symptoms. Two scales, namely:
Clark scale and Vesikari scale which have been used earlier in clin-
ical trials on rotavirus vaccines were used. The Clark scale is a
24-point scale based on duration and frequency of diarrhea and
vomiting, degree and duration of fever measured by rectal tempera-
ture, and description and duration of behavioral symptoms. Axillary
temperature measurements were used instead of rectal measure-
ments. Conversion of axillary temperature to rectal temperature
was performed using following formula [7]: rectal temperature
(◦C) = 0.98 × axillary temperature (◦C) + 0.8 (◦C).
The Clark scale is divided into three ranges: mild <9, moderate
9–16, and severe >16.
The Vesikari scale is a 20-point scale based on duration and
peak frequency of diarrhea and vomiting, degree of temperature,
severity of dehydration, and treatment provided to the patient
(i.e., rehydration or hospitalization). This scale is divided into three
ranges: mild <7, moderate 7–10, and severe ≥11 [8,9].
2.5. Stool sample collection and laboratory analysis
Stool sample (1.5–5 g) was  collected for each subject, prefer-
ably at enrollment, or later but within 14 days of the onset of
AGE symptoms. The stool samples were stored at 2–8 ◦C. Sam-
ples were shipped to The Wellcome Trust Research Laboratory
(Department of Gastrointestinal Sciences, Christian Medical Col-
lege, Vellore, Tamil Nadu), which was the central laboratory for
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his study. The samples were shipped in batches and laboratory
esting occurred after the 14 days follows up of individual subject
as over. Thus, the investigators or the site staff was not aware if
ubject was suffering from RVGE or non-RVGE when AGE related
ata was collected and severity scoring was done.
Stool samples were ﬁrst tested for the presence of rotavirus anti-
en by enzyme immune assay (EIA) using ProspectTM Rotavirus EIA.
he samples that were positive by EIA were genotyped for their
espective G and P types by RT-PCR.
For RT-PCR, viral DNA was extracted from stool specimens and
everse transcribed using random primers to generate complemen-
ary DNA (cDNA). The cDNA was used as a template for genotyping
n hemi-nested multiplex PCRs for VP7 and VP4 genes using pub-
ished primers and protocols [10–14]. The primers could amplify
P7 genotypes: G1, G2, G3, G4, G8, G9, G10, and G12; and VP4
enotypes: P[4], P[6], P[8], P[9], P[10], and P[11].
.6. Ethical conduct
The study was conducted in accordance with the ethical prin-
iples enshrined in the Declaration of Helsinki, International
onference on Harmonization (ICH) – Guideline for Good Clinical
ractice (GCP), and all applicable local regulatory requirements.
he study protocol was approved by the Ethics Committees for
espective sites.
.7. Data analysis
Per protocol (PP) population was used to analyze the study data.
ubjects who had a total data of 14 days, EIA results available, and
ompleted the study as per protocol were included in the PP pop-
lation. The proportion of RVGE among AGE was calculated for
egions and overall (with 95% CI). Data were summarized using
umber and percentages, mean, median and other statistics as
ppropriate. Continuous and categorical variables were compared
cross RV positive and RV negative subjects using Mann–Whitney
 test and Chi-square test, respectively. A p-value <0.05 was
onsidered as statistically signiﬁcant. All statistical analysis was
erformed by SAS software version 9.1.3 (SAS Institute, Cary, NC,
SA).
For planning the study, we assumed that approximately 20%
f enrolled AGE cases might get detected as RV positive and it was
ased on earlier outpatient setting studies in India [15,16]. With this
xpected proportion of rotavirus positivity, 500 was  the targeted
PP) population for enrolling AGE subjects. It was planned that each
egion would provide complete data of at least 100 subjects.
. Results
We  initiated the study at a total of 10 sites with two sites located
n each geographical region (i.e., north, south, east, west, and cen-
er) of India. These sites started enrolling subjects from December
011. Due to inadequate enrollment from one site and region as a
hole, in northern region, we initiated enrollment at an additional
ite in July 2012, taking the total number of sites to 11. Enrollment
t the new site and existing site in the region was competitive.
.1. Study population
We  screened a total of 616 children for eligibility for participa-
ion in this study (Fig. 1). We  found 98.2% (605/616) eligible subjects
nd enrolled them in the study. The study collected stool samples
rom all subjects (n = 605). Site staff contacted the parent/guardian
f all subjects (n = 605) by telephone for data collection after Day
 and Day 14, for collecting information for Day 1–Day 7 and Day
–Day 14, respectively. Out of 552 subjects in PP population, three 32S (2014) A36–A44
sites in north India had 109 (16 + 59 + 34) subjects; two sites each in
south, east, west, and center of India had 99 (47 + 52), 113 (55 + 58),
111 (58 + 53), 120 (45 + 75) subjects, respectively.
From majority of the subjects (89.7% [495/552]) stool samples
were collected within 2 days of enrollment. EIA testing was possible
for samples of 91.2% (552/605) subjects’ stool samples. EIA testing
could not be performed for stool samples of 8.8% (53/605) subjects
for reasons such as insufﬁcient quantity of samples (n = 46), samples
not labeled (n = 4), and inappropriate enrollment (disease symp-
toms occurred >3 days prior to enrollment as opposed to protocol
requirement) (n = 3).
In addition to laboratory results (for EIA), complete per protocol
data was  available for these 552 subjects and they formed the PP
population.
3.2. Demographic characteristics
The demographic characteristics are presented in Table 1. Mean
(±SD) age of subjects was 17.0 (±12.6) months. RV positive subjects
were younger compared to RV negative subjects (mean age ± SD
was 14.8 ± 10.1 months vs. 17.6 ± 13.2 months); this difference was
not statistically signiﬁcant. The distribution of cases by age revealed
statistically signiﬁcant (p = 0.0081) proportion of RV positive cases
in ≤24 months age group. Other baseline characteristics including
gender, ethnicity, family details and income were similar between
RV positive and negative subjects (Table 1).
3.3. Burden of RVGE
Of stool samples of 552 subjects, 23.0% (127/552; [CI 19.5, 26.5])
were found RV positive. Rotavirus positivity was  higher in the
months of January (36.5% [19/52]), February (33.9% [19/56]), and
March (38.7% [36/93]) (Fig. 2). Monthwise enrollment and rotavirus
positivity for total PP population and region-wise is depicted in
Fig. 2.
3.4. Strain characterization
RT-PCR was done for 85.8% (109/127) of RV positive samples
(Fig. 3); for the rest of the samples, RT-PCR could not be done
because of inadequate stool quantity. Among these 109 samples,
we identiﬁed G1, G2, G9, and G12 in 34.9% (38/109), 37.6% (41/109),
8.3% (9/109), and 6.4% (7/109) stool samples, respectively. We  iden-
tiﬁed P[4] and P[8] in 36.7% (40/109) stool samples each, followed
by P[6] identiﬁed in 15.6% (17/109) stool samples. Most common
GP types were G1P[8] and G2P[4] identiﬁed in 32.1% (35/109) and
27.5% (30/109) stool samples respectively.
We  found mixed infection of more than one G type in 6.4%
(7/109) stool samples which were all G1 + G2 type. Mixed P type
infection was  found in 4.6% (5/109) stool samples, which were
P[4] + P[6], P[4] + P[8], and P[8] + P[6] in 1.8% (2/109), 1.8% (2/109),
and 0.9% (1/109) stool samples respectively.
There were also some untypeable strains (G untypeable: 6.4%
[7/109], P untypeable: 6.4% [7/109], and both G and P untypeable:
4.6% [5/109]).
3.5. Clinical data and severity scores
Table 2 describes the presence and duration of AGE  symp-
toms during the study period. At enrollment, we  observed the
co-occurrence of all three symptoms (vomiting, diarrhea, and fever)
in higher proportion of RV positive subjects compared to RV neg-
ative subjects (60.6% [77/127] vs. 42.8% [182/425], p = 0.0004). A
higher proportion of RV negative subjects presented with only
diarrhea (without vomiting and fever) compared to RV positive
subjects (22.8% [97/425] vs. 10.2% [13/127], p = 0.0018).
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The severity of RV positive and negative cases determined
y Clark scale and Vesikari scale is presented in Table 2. The
roportion of subjects with higher AGE severity was statisti-
ally signiﬁcant among RV positive subjects compared to RV
egative subjects by both the scales (Vesikari scale: p = 0.0026,
lark scale: p = 0.0004). For RV positive subjects, the disease was
ild, moderate, and severe for 4.7% (6/127), 18.1% (23/127), and
7.2% (98/127) subjects, respectively by the Vesikari scale. By the
lark scale, disease severity was mild, moderate, and severe for
6.8% (34/127), 69.3% (88/127), and 3.9% (5/127) subjects, respec-
ively.
.6. Healthcare costs due to RV infectionThe total direct cost including costs incurred prior to OPD visit,
n the day of OPD visit, and from OPD till Day 14 were sta-
istically higher (p <0.0001) for RV positive subjects (3177 INR)
ompared with RV negative subjects (1787 INR). The total direct
able 1
aseline characteristics of children presenting with AGE.
Characteristics RV positive (N = 127), n (%)
Age (mean ± SD) (months) 14.8 ± 10.12 
Age (months) 
≤24 109 (85.8) 
>24–≤60 18 (14.2) 
Gender 
Male 84 (66.1) 
Female 43 (33.9) 
Ethnicity (Indian) 127 (100.0) 
Children being breastfed at enrollment 83 (65.4) 
Family type 
Nuclear 86 (67.7) 
Joint 41 (32.3) 
Total members in the family
Median 4 
Family income (mean ± SD) (INR) 321,420.5 ± 349,763.57 
Classiﬁcation of family income (INR) 
≤1,00,000 23 (18.1) 
1,00,001–5,00,000 87 (68.5) 
5,00,001–10,00,000 15 (11.8) 
>10,00,000 2 (1.6) 
Area of residence 
Urban 116 (91.3) 
Rural 11 (8.7) 
or calculating percentage, denominator was the number of subjects in each group (127 i
a Applicable unless otherwise indicated.
b p-value calculated using Mann–Whitney U test.
c p-value calculated using Chi-square test.tion ﬂow chart.
cost incurred for most subjects, i.e., 97.6% (124/127) RV positive
and 98.6% (419/425) RV negative subjects was 10,000 INR or less.
The details of direct costs incurred prior to OPD  visit, on the day
of OPD visit, and subsequent to OPD visit are presented in Table 3.
The total direct cost was higher for subjects who were subsequently
hospitalized (38 RV positive and 50 RV negative) compared to those
who did not require hospitalization. The mean total direct cost for
hospitalized subjects was 7158 INR and 6895 INR for RV positive
and RV negative subjects, respectively. OPD treated subjects had
signiﬁcantly higher (p <0.0001) mean total direct cost in RVGE pos-
itive subjects (1478 INR) as compared to RV negative subjects (1106
INR).
3.7. Healthcare resource utilizationAlmost similar proportions of RV positive (14.2% [18/127]) and
RV negative subjects (11.1% [47/425]) revisited the outpatient facil-
ity at least once after enrollment. Overall, a higher proportion
a RV negative (N = 425), n (%)a p-value
17.6 ± 13.2 0.1312b
0.0081c
317 (74.6)
108 (25.4)
0.2298c
256 (60.2)
169 (39.8)
425 (100.0)
242 (56.9) 0.0909c
0.6306c
278 (65.4)
147 (34.6)
4 0.4481b
345,291.6 ± 69,5417.78 0.8369b
0.2536c
49 (11.5)
318 (74.8)
48 (11.3)
10 (2.4)
0.0357c
408 (96.0)
17 (4.0)
n RV positive group and 425 in RV negative group)
A40 G.S. Namjoshi et al. / Vaccine 32S (2014) A36–A44
Table 2
Clinical presentation and severity of AGE.
Statistics RV positive (N = 127) RV negative (N = 425) p-value
Symptoms presented at enrollment
Only diarrhea n (%) 13 (10.2) 97 (22.8) 0.0018a
Vomiting and diarrhea, without fever n (%) 23 (18.1) 104 (24.5) 0.1351a
Diarrhea and fever, without vomiting n (%) 14 (11.0) 42 (9.9) 0.7086a
Vomiting, diarrhea, and fever n (%) 77 (60.6) 182 (42.8) 0.0004a
Symptoms and duration (in days) experienced over the course of disease
Vomiting n (%) 90 (70.9) 259 (60.9) 0.0418a
Median (days) 2 2 0.0493b
Range (min, max) (days) 1, 5 1, 6
Diarrhea n (%) 127 (100) 425 (100)
Median (days) 4 4 0.3080b
Range (min, max) (days) 2, 11 2, 13
Fever n (%) 78 (61.4) 187 (44.0) 0.0006a
Median (days) 2 2 0.1108b
Range (min, max) (days) 1, 6 1, 7
Abnormal behavior n (%) 119 (93.7) 357 (84.0) 0.0054a
Median (days) 3 3 0.6444b
Range (min, max) (days) 1, 7 1, 10
Vesikari scale 0.0026a
Mild n (%) 6 (4.7) 31 (7.3)
Moderate n (%) 23 (18.1) 137 (32.2)
Severe n (%) 98 (77.2) 257 (60.5)
Clark scale 0.0004a
Mild n (%) 34 (26.8) 193 (45.4)
Moderate n (%) 88 (69.3) 226 (53.2)
Severe n (%) 5 (3.9) 6 (1.4)
For calculating percentage, denominator was the number of subjects in each group. (127 in RV positive group and 425 in RV negative group).
a p-value calculated using Chi-square test.
b p-value calculated using Mann–Whitney U test.
Table 3
Healthcare costs, healthcare resource utilization, and impact of AGE on parents and family of children suffering from AGE.
RV positive N = 127, n (%) RV negative N = 425, n (%) p-value
Direct cost (mean ± SD) (INR)
Pre OPD 676 ± 766.3 580 ± 413.4 0.9124a
OPD visit (Day 1) 1428 ± 1324.5 865 ± 1225.1 <0.0001a
Day 1–Day 7 (subsequent to OPD visit) 1193 ± 1933.2 667 ± 1888.1 0.0066a
Day 8–Day 14 381 ± 3637.8 193 ± 2383.4 0.0040a
Overall 3177 ± 4789.1 1787 ± 4262.2 <0.0001a
Direct cost as per healthcare utilizationb (mean ± SD) (INR)
Hospitalized 7158 ± 7240.7 6895 ± 8321.1 0.3390a
OPD treatment 1478 ± 1015.4 1106 ± 2751.5 <0.0001a
Healthcare utilization
OPD followed by hospitalization 38 (29.9) 50 (11.8) <0.0001c
OPD 89 (70.1) 375 (88.2)
Repeat outpatient visit 18 (14.2) 47 (11.1) 0.3393c
IV hydration 39 (30.7) 53 (12.5) <0.0001c
Telephonic call to physician 4 (3.1) 35 (8.2) 0.0497c
Number of work days lost <0.0001c
0.5–3 35 (27.6) 62 (14.6)
≥3  9 (7.1) 11 (2.6)
Monetary impact of availed leaves (INR) 0.0008d
<1000 28 (22.0) 48 (11.3)
≥1000 to <5000 15 (11.8) 25 (5.9)
≥5000 1 (0.8) 3 (0.7)
Occurrence of GE in householde
1 2 (1.6) 0
2  1 (0.8) 1 (0.2)
For calculating percentage, denominator was the number of subjects in each group. (127 in RV positive group and 425 in RV negative group).
a p-value calculated using Mann–Whitney U test.
b For “Direct cost as per healthcare utilization”, number of subjects hospitalized were: (N = 88) (RV positive = 38, RV negative = 50); and number of subjects who attended
OPD  only were: (N = 464) (RV positive = 89, RV negative = 375).
c p-value calculated using Chi-square test.
d p-value calculated using Fisher’s exact test.
e Includes the number of family members reporting GE symptoms from 2 weeks before the enrollment visit up to 2 weeks after enrollment visit, i.e., Day 14.
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p <0.0001) of RV positive subjects (29.9% [38/127]) were hos-
italized compared with (11.8% [50/425]) RV negative subjects.
f the 38 RV positive subjects who were hospitalized, only one
ubject (2.6% [1/38]) was severe by Clark scale, and 35 subjects
92.1% [35/38]) were severe by Vesikari scale. Compared with
V negative subjects, a higher proportion of RV positive sub-
ects were given IV hydration (12.5% [53/425] vs. 30.7% [39/127],
 <0.0001).
.8. Impact on parents and family
The data describing parental work loss attributed to the AGE
f children are presented in Table 3. Parents/guardians of 23.6%
30/127) RV positive subjects lost 2 or more days of work compared
ith parents/guardians of 12.0% (51/425) RV negative subjects. We
oted monetary impact of leave availed by parents/guardians for a
igher proportion of RV positive children compared with RV nega-
ive children.
ig. 2. Month-wise recruitment and rotavirus positivity. Footnote: the numbers at the top
otal  enrollment and rotavirus detection results for respective regions. 32S (2014) A36–A44 A41
We determined the median value of stress score to be 5 for par-
ents of RV positive as well as RV negative subjects through 14 days.
Similarly, we  also scored the stress suffered by parents when their
child’s disease was  at its peak, and noted that at the peak of the
disease, the stress levels of parents of RV positive subjects were
higher compared to RV negative subjects (median values 9 vs. 8,
p < 0.0001).
4. Discussion
Rotavirus disease burden studies in India have evaluated chil-
dren who  are hospitalized but these studies fail to represent the
full burden of disease. We  planned this study with a focus on
enrollment of pediatric subjects with AGE when they attend pri-
vate outpatient clinics in urban areas of the country. Results of this
study conﬁrm that RVGE is a major cause of AGE among Indian
children in the outpatient setting as 23% (127/552) of all AGE cases
were detected rotavirus positive. In present study there were some
 of bar indicate total recruitment in respective month. Bars on extreme right depict
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ases that got hospitalized after enrollment at OPD in both rotavirus
nd non-rotavirus groups which were anticipated as the study was
lanned to enroll eligible children at OPD and treatment thereafter
as as per investigator’s practice. The burden of RVGE among only
PD managed AGE cases was found to be 19.2%, proportion similar
o earlier two studies wherein RVGE was found in 15.5% and 22%
f AGE cases treated in OPDs [15,16]. Proportion of RVGE among
GE hospitalized cases was  43.2% (38 out of 88 cases). This burden
s also similar to earlier studies on rotavirus burden in hospitalized
GE cases [5,6].
We found G1 and G2 as the most common G types, P[4] and
[8] as the most common P types and G1P[8] and G2P[4] as com-
on  GP types. Some rotavirus samples could not be typed for
 and/or P type. The most common G/P/GP types found in this
tudy are similar to other Indian studies (including IRSN) conducted
n children hospitalized with RVGE [2–6]. Our results show that
12 comprised 6.4% of rotavirus strains: a ﬁnding in concordance
ith IRSN [4,6]. G12 strain was ﬁrst detected in India in 2001 and
ver the decade has been increasingly reported in recent Indian
tudies [4,6,17,18].inued)
More than 75% of the children enrolled in the study were in the
age group of less than 2 years. This reﬂects the age proﬁle of diar-
rhea burden in India, where majority of the diarrhea episodes in
children under 5 years of age are reported to occur in children of
age less than 3 years [19,20]. In our study, mean age of RV positive
subjects was lower compared to RV negative subjects and majority
of RVGE (85%) cases occurred in children ≤24 months of age. The
difference between rotavirus and non-rotavirus groups was signiﬁ-
cant w.r.t. age distribution – result similar to previous observations
of the epidemiologic proﬁle of rotavirus infection in India [4,5]. In
IRSN, it was observed that the mean age of RV positive children was
signiﬁcantly lower than RV negative children.
In addition to younger age of RVGE subjects, our results also
indicate that RV positive subjects experience severe and multiple
AGE symptoms. We  found that more than half of the RVGE cases
were severe by Vesikari scale (77.2%) while a few were severe
by Clark scale (3.9%). Similar distribution was seen in non-RVGE
cases. Higher proportion of severe cases in our study may  be due
to late referral of the subjects to OPDs after disease onset. A 10
district survey in India by UNICEF titled “Management Practices of
G.S. Namjoshi et al. / Vaccine 32S (2014) A36–A44 A43
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eig. 3. Distribution of G, P, and GP types. Footnote – others include 1.8% each of the
ypes:  G12 P[8], G1 P[6], G2 P[8], G12 P[4], G1 + G2 P[8], G2 P[4] + P[6], G2 P[4] + P[8
hildhood Diarrhea in India” has reported that in India in rural as
ell as urban areas, there is delay of at least 1 day between onset of
iarrhea and time of seeking medical care outside home. The report
lso mentions that parents took the child outside home for manag-
ng diarrhea when child had too many stools, appeared very weak,
id not eat anything, and diarrhea continued for too long [20]. It is
ikely therefore that majority of parents take their child to health
are setting when diarrhea becomes severe. We  used Clark and
esikari scale for categorizing acute gastroenteritis into different
everity levels. This categorization is dependent on multiple factors
ike study methodology such as where, how and when data is col-
ected, active or passive method surveillance and frequency, timing,
ethod of assessment in active studies. The sources of information
n duration and treatment also inﬂuence the data from which a
core is calculated [21]. We  followed up the child till 14 days after
nrollment and there was daily record of symptoms by the parents.
robably this makes the study highly sensitive and obtained the
etailed information of the duration and frequency of symptoms
f AGE. Finding of more severe cases by Vesikari scale as compared
o Clark scale is similar to earlier studies that have used both scales.
he Vesikari scale more frequently scores gastroenteritis episodes
s severe as compared to the Clark scale [8,9,21].
All severe cases were not hospitalized in our study. The decision
o hospitalize a child is based mainly on requirement of supervised
ehydration as determined by the treating physician. In addition,
actors like economic condition of parents and distance between
ome and healthcare setting inﬂuence decision of hospitalization
21]. It is evident from our study that in diarrheal disease and
specially in RVGE, taking early treatment from health care set-
ing would be of utmost importance to prevent complications of
isease.
Our study suggests that RVGE places a considerable ﬁnancial and
motional burden on parents of the affected children and they lost
p to 7 days of work. The RVGE cases had higher healthcare cost
nd difference between RVGE and non RVGE cases was  signiﬁcant
n OPD managed cases. Our results show that pediatric RVGE caused
onsiderable stress for parents. This is consistent with results of a
tudy conducted across European countries where stress scores of
5 on 10-point scale were reported irrespective of settings under
hich the child was treated [22].
Though study provides substantial data on RVGE in speciﬁed set-
ing and overall proportion of RVGE is in concurrence with earlier
tudies, the results of this study need to be interpreted with cau-
ion because of certain important limitations. Study was conducted
nly in private outpatient clinics in urban areas of India and is not
epresentative of rural and non-private healthcare settings such
s government healthcare facilities or non-proﬁt hospitals/clinics.
hese settings might have different rotavirus disease proﬁle and
conomic impact on subjects who utilize these services may  bewing types: G1 P[4], G9 P[8], G1 + G2 P[6], G1 + G2 P[4]; and 0.9% each of following
[8] + P[6], G1 + G2 P[4] + P[6], G9 UT, G1 + G2 UT, UT P[6], UT P[4] + P[8].
different. It is noteworthy however that in our study, the private
and urban setting has shown RVGE as important health problem,
reafﬁrming the universal occurrence of RVGE.
IRSN data has shown that though rotavirus disease occurs
throughout the year, higher proportion is observed in winter sea-
son (December–February) particularly in northern India. It has
also been shown that proportion of rotavirus disease is higher in
younger age and more severe cases [4]. Even in our study, when
total PP population was  considered, we did ﬁnd that RVGE is asso-
ciated with younger age, multiple symptoms, more severity of the
disease as per Clark and Vesikari scale and higher proportion in the
months of January–March. The enrollment period across the study
sites also varied as some sites completed the study in a few months,
while some sites continued the study for 11 months as the monthly
enrollment was less. The enrollment criteria in our study were not
restrictive as mentioned in study population above. Accordingly
the difference in enrollment w.r.t. age, severity of AGE and month
of enrollment across sites/regions might have led to wide variation
in proportion of RVGE across regions. The overall study duration
was less than 1 year; therefore annual patterns in the rotavirus
strains could not be ascertained.
Despite these limits the study has obvious strengths: we  used
uniform protocol across the sites and well-established central labo-
ratory support for RV diagnosis and typing; we  used diary cards and
questionnaires to understand the entire spectrum of the disease
from its onset and also economic and psychological impact associ-
ated with it. We focused the study on RGVE disease in urban private
clinics which has previously been under researched. To our knowl-
edge this is the ﬁrst well designed multicentric study to provide
data on RVGE burden in urban private OPD setting among children
with AGE in India.
5. Conclusion
We conclude that a high proportion of rotavirus among AGE
cases attend pediatric outpatient clinics in urban areas of India. This
is associated with substantial economic and psychological burden
caused by RVGE. The results support that there is deﬁnite need of
well tolerated and effective rotavirus vaccine for all eligible chil-
dren in India.
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